BNP Paribas Financial Markets Purchases 122,136 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

BNP Paribas Financial Markets raised its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 373.1% in the fourth quarter, Holdings Channel reports. The fund owned 154,873 shares of the biopharmaceutical company’s stock after buying an additional 122,136 shares during the quarter. BNP Paribas Financial Markets’ holdings in Dynavax Technologies were worth $1,978,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. SG Americas Securities LLC bought a new stake in Dynavax Technologies during the fourth quarter valued at about $990,000. Palumbo Wealth Management LLC acquired a new position in shares of Dynavax Technologies during the fourth quarter valued at about $275,000. Barclays PLC raised its position in shares of Dynavax Technologies by 137.4% during the third quarter. Barclays PLC now owns 302,572 shares of the biopharmaceutical company’s stock valued at $3,371,000 after buying an additional 175,118 shares during the last quarter. Schonfeld Strategic Advisors LLC raised its position in shares of Dynavax Technologies by 97.6% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 310,430 shares of the biopharmaceutical company’s stock valued at $3,964,000 after buying an additional 153,302 shares during the last quarter. Finally, First Trust Advisors LP acquired a new position in shares of Dynavax Technologies during the fourth quarter valued at about $847,000. 96.96% of the stock is currently owned by institutional investors.

Dynavax Technologies Stock Performance

NASDAQ:DVAX opened at $9.67 on Friday. Dynavax Technologies Co. has a 12-month low of $9.22 and a 12-month high of $14.63. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $1.16 billion, a PE ratio of 53.72 and a beta of 1.26. The firm has a 50-day moving average price of $11.78 and a 200 day moving average price of $12.51.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.14). Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The business had revenue of $68.16 million during the quarter, compared to analyst estimates of $70.01 million. Research analysts anticipate that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently commented on DVAX shares. StockNews.com lowered shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, May 6th. HC Wainwright reaffirmed a “buy” rating and set a $31.00 price objective on shares of Dynavax Technologies in a research report on Friday, February 21st. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 21st. JMP Securities cut their price objective on shares of Dynavax Technologies from $33.00 to $31.00 and set a “market outperform” rating for the company in a research report on Wednesday, May 7th. Finally, The Goldman Sachs Group cut their price objective on shares of Dynavax Technologies from $12.00 to $10.00 and set a “sell” rating for the company in a research report on Thursday, April 17th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $24.00.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.